ADA 2026: Breakthroughs in Incretin Therapy, Liver Disease & Cardiovascular Risk Reduction
At the 2026 American Diabetes Association (ADA) conference, incretin therapies demonstrated significant advancements in metabolic liver disease management and cardiovascular risk reduction, according to clinical data reviewed by the Endocrine ... Read More